FindTrial
Sign In

Evaluation for the safety and efficacy of guidance in screening chemotherapeutic drugs and conventional drug in the treatment of postoperative adjuvant TACE for patients of hepatocellular carcinoma

Evaluation for the safety and efficacy of guidance in screening chemotherapeutic drugs and conventional drug in the treatment of postoperative adjuvant TACE for patients of hepatocellular carcinoma

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800020412
Enrollment
Unknown
Registered
2018-12-28
Start date
2019-01-01
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Carcinoma

Interventions

EG:Screening assay for chemotherapy
CG:Nono

Sponsors

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Understand and sign the informed consent; 2. Aged 18-80 years men and women; 3. pathological diagnosis of hepatocellular carcinoma; 4. BCLC stage was A or B stage; 5. Child-Pugh was A-B

Exclusion criteria

Exclusion criteria: 1. Child-Pugh level C; 2. Patients with congenital or acquired immunodeficiency (eg.HIV infectors) 3. The patients had other malignant tumors in the past 3 years (except for cured skin basal cell carcinoma and cervical carcinoma in situ); 4. Complications or social environment that can lead the failure of the subjects to follow the study plan and even endanger the safety of the patients.

Design outcomes

Primary

MeasureTime frame
overall survival;disease free survival;1 year survival rate;—

Countries

China

Contacts

Public ContactXiujun Cai

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine

srrsh_cxj@zju.edu.cn+86 0571 86006634

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026